Reports
Reports
The global methicillin-susceptible staphylococcus aureus market (MSSA) is anticipated to witness moderate growth during the forecast period between 2021 and 2031.
MSSA is an infection caused by gram-positive bacteria and leads to skin allergies, endocarditis, and pneumonia. The gram-positive bacteria release beta-lactamase, which plays a key role in causing the infection in a person.
A few symptoms of MSSA infections include fever, diarrhoea, painful rushes, cellulitis, nausea, and vomiting.
In addition to this, the central nervous system is the most affected part of the body when a patient suffers from an MSSA infection.
Rising morbidity and mortality rate of MSSA infection worldwide is the key growth driver for MSSA market.
Also, growing awareness about the MSSA infection among different population sections is expected to contribute to the growth of the overall market, in future.
In addition to this, government initiatives and measures creating awareness about the infection and providing information about the treatment for it could bolster the MSSA market, in the coming years.
Semi-synthetic penicillin treatment method is anticipated to contribute the most to the overall MSSA market in future because the speed of recovery from the infection by using these drugs has proven to be faster than other available treatment methods,
Hospitals and clinics' end-use segments are expected to make the largest contribution to the overall MSSA market due to increasing number of patients suffering from MSSA infection coming to these facilities for treatment.
The global MSSA market is still consolidated, with the presence of few well-established market players. These players are expected to engage in different growth strategies such as novel product launches, in a bid to remain competitive in the overall market.
Cellcutix Corporation has manufactured a drug named Brilacidin, which helps in providing treatment against skin structure infection and acute bacterial skin, which is developed by the MSSA infection.
The smaller players will seek investments from governments and private investors, which could help them in their long-term growth.
These players could deploy the funding for research and development activities in a bid to produce improved quality of products, which would meet the requirements of a large number of consumers.
A few leading players in the global MSSA market include Lytix Biopharma AS, Cellcutix Corporation, Cubist Pharmaceuticals, and Immtech Pharmaceuticals Inc.
The global MSSA market is classified into five regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Europe is expected to be the dominant region in the global MSSA market because of increasing number of patients suffering from MSSA infection in countries such as Italy and Germany.
North America is expected to offer lucrative growth opportunities for the global market in the coming years owing to factors such as superb healthcare infrastructure in countries such as US, Mexico, and Canada and the presence of leading MSSA market players in these countries.
Asia Pacific is expected to witness moderate growth in future because of developing healthcare infrastructure facilities in countries such as India and Thailand and a lack of awareness about this infection in developing economies, part of the region.
Leading players could look to establish healthcare facilities as well as R&D centers in countries such as India in future because of ease of availability of key resources such as land and labor, which could contribute to market growth.
Other parts of the world such as Middle East and Africa and Latin America are anticipated to witness sluggish growth in the overall MSSA market, in the years ahead owing to lack of presence of well-established market players in countries belonging to both regions.
N/A
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Market
